Sms Lifesciences India Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
- Paid Up Capital ₹ 3.02 Cr
- Company Age 18 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 111.27 Cr
- Satisfied Charges ₹ 40.00 Cr
- Revenue Growth -8.36%
- Profit Growth -47.92%
- Ebitda 142.27%
- Net Worth 8.47%
- Total Assets 8.14%
About Sms Lifesciences India
Sms Lifesciences India Limited (SLIL) is a leading Public Limited Indian Non-Government Company incorporated in India on 31 May 2006 and has a history of 18 years and eight months. Its registered office is in Hyderabad, Telangana, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 540679 and on the National Stock Exchange(NSE) under SMSLIFE.
The Corporate was formerly known as Sms Lifesciences India Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.50 Cr and a paid-up capital of Rs 3.02 Cr.
The company currently has active open charges totaling ₹111.27 Cr. The company has closed loans amounting to ₹40.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Sms Lifesciences India Limited India are Trupti Mohanty as COMPANY SECRETARY and Mr Prasad as Cfo. Veeravenkata Talluri, Mannam Malakondaiah, Sarath Pakalapati, and Three other members serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
Industry
Who are the key members and board of directors at Sms Lifesciences India?
Executive Team (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Veeravenkata Talluri ![]() | Managing Director | 01-Apr-2016 | Current |
Trupti Mohanty | Company Secretary | 14-Feb-2020 | Current |
Mr Prasad ![]() | CFO | 01-Jun-2017 | Current |
Board Members (5)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Sarath Pakalapati ![]() | Director | 25-May-2017 | Current |
Mannam Malakondaiah ![]() | Director | 13-Nov-2021 | Current |
Srinivas Samavedam ![]() | Director | 13-Nov-2021 | Current |
Venkata Talluri ![]() | Whole-Time Director | 21-Aug-2020 | Current |
Sudeepthi Gopineedi ![]() | Whole-Time Director | 02-Sep-2021 | Current |
Financial Performance of Sms Lifesciences India.
Sms Lifesciences India Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 8.36% decrease. The company also saw a substantial fall in profitability, with a 47.92% decrease in profit. The company's net worth moved up by a moderate rise of 8.47%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Sms Lifesciences India?
In 2023, Sms Lifesciences India had a promoter holding of 70.32% and a public holding of 29.67%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹111.27 Cr
₹40.00 Cr
Charges Breakdown by Lending Institutions
- Others : 61.27 Cr
- Hdfc Bank Limited : 50.00 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
12 Aug 2022 | Hdfc Bank Limited | ₹30.00 Cr | Open |
31 Mar 2022 | Hdfc Bank Limited | ₹20.00 Cr | Open |
29 Mar 2022 | Others | ₹3.44 Cr | Open |
16 Mar 2021 | Others | ₹7.83 Cr | Open |
25 Sep 2018 | Others | ₹20.00 Cr | Open |
How Many Employees Work at Sms Lifesciences India?
Sms Lifesciences India has a workforce of 558 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Sms Lifesciences India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sms Lifesciences India's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.